Imaging and clinical outcome of non-small cell lung cancer

Kerner, G. S. M. A., 2016, [Groningen]: Rijksuniversiteit Groningen. 183 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 476 KB, PDF document

  • Chapter 1

    Final publisher's version, 776 KB, PDF document

  • Chapter 2

    Final publisher's version, 4 MB, PDF document

  • Chapter 3

    Final publisher's version, 3 MB, PDF document

  • Chapter 4

    Final publisher's version, 2 MB, PDF document

  • Chapter 5

    Final publisher's version, 1 MB, PDF document

  • Chapter 6

    Final publisher's version, 1 MB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Chapter 8

    Final publisher's version, 1 MB, PDF document

  • Chapter 9

    Final publisher's version, 865 KB, PDF document

  • Chapter 10

    Final publisher's version, 928 KB, PDF document

  • Curriculum Vitae

    Final publisher's version, 618 KB, PDF document

  • Dankwoord

    Final publisher's version, 867 KB, PDF document

  • Complete thesis

    Final publisher's version, 20 MB, PDF document

  • Propositions

    Final publisher's version, 43 KB, PDF document

  • Gerald Steve Michael Alexander Kerner
Gerald Kerner, born in Curaçao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.
He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.
He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.
Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date11-May-2016
Place of Publication[Groningen]
Print ISBNs978-90-367-8834-2
Electronic ISBNs978-90-367-8833-5
Publication statusPublished - 2016

Download statistics

No data available

ID: 31906608